In our February 27 story "Uniting biotech with pharma," we stated that Nektar Therapeutics was not mentioned in a front page New York Times article on Exubera. In fact, it was mentioned in that story.
In the PRWeek feature story, we used the article in the January 28th issue of the New York Times erroneously, as an example of a biotech company not leveraging its relationship with a pharma company for PR value.
Our story was mistaken in the fact, and in the assumption, and we deeply regret the error. We apologize to Nektar Therapeutics, in particular, for this mistake. The fault was entirely ours.
The corrected story appears here.